Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

DRRX:US

2.6000 USD 0.0100 0.38%

As of 20:10:00 ET on 05/29/2015.

Snapshot for Durect Corp (DRRX)

Open: 2.6500 Day's Range: 2.5000 - 2.7200 Volume: 1,493,126
Previous Close: 2.6100 52wk Range: 0.6800 - 2.7200 1-Yr Rtn: +89.78%

Stock Chart for DRRX

No chart data available.
  • DRRX:US 2.6000
  • 1D
  • 1M
  • 1Y
2.6100
Interactive DRRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DRRX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.2000
Est. EPS (USD) (12/2015) -0.2450
Est. PEG Ratio -
Market Cap (M USD) 310.88
Shares Outstanding (M) 119.57
30 Day Average Volume 887,665
Price/Book (mrq) 20.0891
Price/Sale (ttm) 16.3528
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DRRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DRRX

Durect Corporation develops and commercializes pharmaceutical systems for the treatment of chronic diseases. The pharmaceutical systems provide therapy for chronic diseases or conditions by replacing multiple injection therapy or oral dosing, improving drug efficacy, reducing side effects, and ensuring dosing compliance.

Felix TheeuwesChairman/Chief Scientific OfcrJames E BrownPresident/CEO/Co-Founder
Matthew J HoganCFO/SecretaryJudy R JoiceSenior VP:Operations
More Company Profile & Key Executives for DRRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil